Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

A new study found that aged neurons have defects in key proteins that make them vulnerable to molecular stress and neurodegenerative damage.

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy volunteers.

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Bora Pharmaceuticals also offers lyophilization, terminal sterilization, analytical, stability, and packaging and serialization services.